[go: up one dir, main page]

WO1996038571A3 - Recombinant polypeptide cytotoxins for cancer treatment - Google Patents

Recombinant polypeptide cytotoxins for cancer treatment Download PDF

Info

Publication number
WO1996038571A3
WO1996038571A3 PCT/US1996/008313 US9608313W WO9638571A3 WO 1996038571 A3 WO1996038571 A3 WO 1996038571A3 US 9608313 W US9608313 W US 9608313W WO 9638571 A3 WO9638571 A3 WO 9638571A3
Authority
WO
WIPO (PCT)
Prior art keywords
recombinant polypeptide
cytotoxins
cancer treatment
polypeptide cytotoxins
cytokine
Prior art date
Application number
PCT/US1996/008313
Other languages
French (fr)
Other versions
WO1996038571A2 (en
Inventor
Fatih M Uckun
John P Perentesis
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Priority to AU59652/96A priority Critical patent/AU5965296A/en
Publication of WO1996038571A2 publication Critical patent/WO1996038571A2/en
Publication of WO1996038571A3 publication Critical patent/WO1996038571A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Recombinant polypeptide cytotoxins are provided which comprise a cytokine or cytokine subunit or a single chain antibody subunit fused to a polypeptide toxin which suppress the proliferation of a population of mammalian cells by causing apoptotic cell death. The invention further provides a method which utilizes the disclosed recombinant polypeptide cytotoxins to systemically treat cancer patients.
PCT/US1996/008313 1995-05-31 1996-05-31 Recombinant polypeptide cytotoxins for cancer treatment WO1996038571A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU59652/96A AU5965296A (en) 1995-05-31 1996-05-31 Recombinant polypeptide cytotoxins for cancer treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45526395A 1995-05-31 1995-05-31
US08/455,263 1995-05-31

Publications (2)

Publication Number Publication Date
WO1996038571A2 WO1996038571A2 (en) 1996-12-05
WO1996038571A3 true WO1996038571A3 (en) 1997-02-20

Family

ID=23808103

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/008313 WO1996038571A2 (en) 1995-05-31 1996-05-31 Recombinant polypeptide cytotoxins for cancer treatment

Country Status (2)

Country Link
AU (1) AU5965296A (en)
WO (1) WO1996038571A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL116436A (en) 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND
DE19735105A1 (en) * 1997-08-13 1999-03-04 Univ Albert Ludwigs Freiburg New fusion protein
US6645490B2 (en) 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
US6168932B1 (en) 1998-07-13 2001-01-02 Parker Hughes Institute Recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system
WO2002097042A2 (en) * 2001-05-25 2002-12-05 The Trustees Of The University Of Pennsylvania Chimeric proteins for cell targeting and apoptosis induction and methods of using the same
EP1492560A4 (en) 2002-04-10 2007-05-30 Zymogenetics Inc Use of interleukin-19 to treat cervical cancer
WO2008030539A2 (en) 2006-09-07 2008-03-13 Frankel Arthur E Methods and compositions based on diphtheria toxin-interleukin-3 conjugates

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009613A1 (en) * 1990-12-03 1992-06-11 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diphtheria toxin
WO1993007286A1 (en) * 1991-09-30 1993-04-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Recombinant immunotoxins
WO1993025228A1 (en) * 1992-06-15 1993-12-23 Whittier Institute For Diabetes And Endocrinology Cytotoxins specific for gm-csf receptor-bearing cells
WO1996005865A1 (en) * 1994-08-22 1996-02-29 Regents Of The University Of Minnesota Combination immunotoxin/antineoplastic agent therapy for b-lineage cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009613A1 (en) * 1990-12-03 1992-06-11 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diphtheria toxin
WO1993007286A1 (en) * 1991-09-30 1993-04-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Recombinant immunotoxins
WO1993025228A1 (en) * 1992-06-15 1993-12-23 Whittier Institute For Diabetes And Endocrinology Cytotoxins specific for gm-csf receptor-bearing cells
WO1996005865A1 (en) * 1994-08-22 1996-02-29 Regents Of The University Of Minnesota Combination immunotoxin/antineoplastic agent therapy for b-lineage cancer

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
B.E. BEJCEK ET AL: "Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen", CANCER RESEARCH, vol. 55, no. 11, 1 June 1995 (1995-06-01), MD US, pages 2346 - 2351, XP002019021 *
C.-H. CHAN ET AL: "A murine cytokine fusion toxin specifically targeting the murine Granulocyte-Macrophage Colony-Stimulating Factor(GM-CSF) receptor on normal committed bone marrow progenitor cells and GM-CSF-dependent tumor cells", BLOOD, vol. 86, no. 7, 1 October 1995 (1995-10-01), pages 2732 - 2740, XP000611396 *
C.-H. CHAN ET AL: "reactivity of murine cytokine fusion toxin, diphtheria toxin390-murine interleukin-3 (DT390-miL-3), with bone marrow progenitor cells", BLOOD, vol. 88, no. 4, 15 August 1996 (1996-08-15), pages 1445 - 1456, XP000611395 *
D.E. CHADWICK ET AL: "Cytotoxicity of a recombinant Diphtheria toxin-Granulocyte Colony-Stimulating Factor fusion protein on human leukemic blast cells", LEUKEMIA AND LYMPHOMA, vol. 11, no. 3, 1993, pages 249 - 262, XP000611501 *
D.E. MYERS ET AL: "Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP,directed against the CD19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 136, 1991, pages 221 - 238, XP002019020 *
D.P. WILLIAMS ET AL: "Diphtheria toxin receptor binding domain substitution with Interleukin-2 : genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein", PROTEIN ENGINEERING, vol. 1, no. 6, 1987, ENGLAND GB, pages 493 - 498, XP002019018 *
F.M. UCKUN ET AL: "In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein Immunotoxin against human pre-B cell acute lymphoblastic Leukemia in mice with severe combined immunodeficiency", BLOOD, vol. 79, no. 9, 1 May 1992 (1992-05-01), pages 2201 - 2214, XP000611286 *
F.M. UCKUN ET AL: "Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia", JOURNAL OF EXPRIMENTAL MEDICINE, vol. 163, February 1986 (1986-02-01), pages 347 - 368, XP000611309 *
J.P. PERENTESIS ET AL: "Protein toxin inhibitors of protein synthesis", BIOFACTORS, vol. 3, no. 3, January 1992 (1992-01-01), pages 173 - 184, XP000611278 *
J.P.PERENTESIS ET AL: "Apoptotic killing of chemotherapy and radiation-resistant human myeloid leukemias by a recombinant fusion toxin targeted to the granulocyte macrophage colony stimulating factor receptor", BLOOD, vol. 86, no. 10 suppl1, 15 November 1995 (1995-11-15), pages 436a, XP000611507 *
M.C. FUNG ET AL: "Molecular cloning of cDNA for murine Interleukin-3", NATURE, vol. 307, no. 5948, January 1984 (1984-01-01), LONDON GB, pages 233 - 237, XP002019019 *
R. GUNTHER ET AL: "Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin", BLOOD, vol. 85, no. 9, 1 May 1995 (1995-05-01), pages 2537 - 2545, XP000611369 *
U. BRINKMANN ET AL: "Immunotoxins against cancer", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1198, 1994, pages 27 - 45, XP000564482 *

Also Published As

Publication number Publication date
AU5965296A (en) 1996-12-18
WO1996038571A2 (en) 1996-12-05

Similar Documents

Publication Publication Date Title
AU5930396A (en) Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
AU573523B2 (en) Functional human urokinase proteins
AU5958996A (en) Monoclonal antibodies for human mesenchymal stem cells
AU6916296A (en) Recombinant anti-cd4 antibodies for human therapy
AU7327596A (en) Preparation of phosphorothioate oligomers
AU1496288A (en) Recombinant ricin toxin fragments
IL124689A0 (en) Apoptosis induced by monoclonal antibody anti-her2
AU2608292A (en) Human immunoglobulins produced by recombinant dna techniques
AU3125289A (en) Monoclonal antibodies directed against human tumor necrosis factor - receptor
IL132249A0 (en) Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins
ZA200200789B (en) Multiple cytokine-antibody complexes.
CA2072249A1 (en) Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
EP0675904A4 (en) HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST HUMAN IMMUNODEFICIENCY VIRUS.
WO1996038571A3 (en) Recombinant polypeptide cytotoxins for cancer treatment
WO1997025071A3 (en) Immunoconjugate for the treatment of aids
WO1998006827A3 (en) Method for immortalizing cells
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases
AU2383288A (en) Human anti-rh(d) monoclonal antibodies
AU542296B2 (en) Biologically active peptides
TW372873B (en) A novel anti-neoplastic cytokine
AU6059194A (en) Monoclonal antibodies to bovine cytokines
HUT73213A (en) Method for recombinant production of biologically active polypeptides
EP0270077A3 (en) Antibody to exotoxin of pseudomonas aeruginosa and gene therefor
IL85471A0 (en) Monoclonal antibodies to human pancreatic cancer,their production and hybridoma cell lines secreting them
MX9802380A (en) SHORT FORMS OF CHEMOKINE 'beta'-8

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA